Improving Outcomes for Patients With High-Risk, HR-Positive/HER2-Negative Early Breast Cancer: Education and Resources for the Multidisciplinary Team

Improving Outcomes for Patients With High-Risk, HR-Positive/HER2-Negative Early Breast Cancer: Education and Resources for the Multidisciplinary Team is organized by Clinical Care Options (CCO), LLC.,Released: March 14, 2023,Expiration: March 13, 2024,Program Learning Goal:,The goal of this educational curriculum is to improve the knowledge, competence, and performance of learners to optimally assess the risk of patients with HR-positive/HER2-negative early breast cancer and select optimal individualized therapy for those with higher-risk disease.,Learning Objectives:,After completing this activity, participants should be better able to:,• Incorporate the evidence on the current use of Ki67 as a predictive and prognostic biomarker into clinical practice,• Identify patients with high-risk features who may benefit from the addition of CDK4/6 inhibitor therapy to endocrine therapy in the adjuvant setting,• Foster collaborative discussions and workflows between the oncology multidisciplinary team and patients to guide personalized treatment planning for HR-positive/HER2-negative early breast cancer,• Promote strategies to ensure optimal adherence and persistence to prescribed oral CDK4/6 inhibitors in patients with early-stage breast cancer,• Manage adverse events associated with oral targeted therapy in the adjuvant setting for patients with HR-positive/HER2-negative breast cancer,Additional details will be posted as soon as information is available.